Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202
- Citation:
- Blood vol 132 (Suppl 1) 6
- Meeting Instance:
- ASH 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3028
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180820, U10CA180790, U10CA180888
- Corr. Author:
- Authors:
- Jennifer A. Woyach Amy S. Ruppert Nyla Heerema Weiqiang Zhao Allison M Booth Wei Ding Nancy Bartlett Danielle M Brander Paul M Barr Kerry A Rogers Sameer Parikh Steven Coutre Arti Hurria Gerard Lozanski Sreenivasa Nattam Richard A. Larson Harry Erba Mark Litzow Carolyn Owen James Atkins Jeremy Abramson Richard M. Stone Sumithra Mandrekar John C. Byrd
- Networks:
- LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-OH007, NC002, NY167, OH070
- Study
- Alliance-A041202
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: